Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma

Our study aimed to explore the efficacy and safety of anlotinib–toripalimab combination therapy as a second-line treatment for advanced relapsed gastric or gastroesophageal junction carcinoma (GC/GEJC). In this single arm, single-center extension clinical trial, patients with advanced relapsed GC/GE...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Man, Zhang, Chuantao, Hu, Yabin, Li, Tianjun, Yang, Guangjie, Wang, Guanqun, Zhu, Jingjuan, Shao, Changfeng, Hou, Helei, Zhou, Na, Liu, Kewei, Zhang, Xiaochun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Gastrointestinal Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632317/
https://www.ncbi.nlm.nih.gov/pubmed/35857405
http://dx.doi.org/10.1093/oncolo/oyac136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632317/
https://www.ncbi.nlm.nih.gov/pubmed/35857405
http://dx.doi.org/10.1093/oncolo/oyac136

Ejemplares similares